KR20150039201A - 체외 막 산소공급에서의 안티트롬빈의 용도 - Google Patents

체외 막 산소공급에서의 안티트롬빈의 용도 Download PDF

Info

Publication number
KR20150039201A
KR20150039201A KR1020157002667A KR20157002667A KR20150039201A KR 20150039201 A KR20150039201 A KR 20150039201A KR 1020157002667 A KR1020157002667 A KR 1020157002667A KR 20157002667 A KR20157002667 A KR 20157002667A KR 20150039201 A KR20150039201 A KR 20150039201A
Authority
KR
South Korea
Prior art keywords
antithrombin
administered
units
produced
extracorporeal membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157002667A
Other languages
English (en)
Korean (ko)
Inventor
조한 프리엘링
사이먼 로우리
Original Assignee
엘에프비 유에스에이, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘에프비 유에스에이, 인크. filed Critical 엘에프비 유에스에이, 인크.
Publication of KR20150039201A publication Critical patent/KR20150039201A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157002667A 2012-08-03 2013-08-02 체외 막 산소공급에서의 안티트롬빈의 용도 Ceased KR20150039201A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
US61/679,345 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (1)

Publication Number Publication Date
KR20150039201A true KR20150039201A (ko) 2015-04-09

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002667A Ceased KR20150039201A (ko) 2012-08-03 2013-08-02 체외 막 산소공급에서의 안티트롬빈의 용도

Country Status (13)

Country Link
US (1) US9511087B2 (https=)
EP (1) EP2879697A4 (https=)
JP (1) JP6389172B2 (https=)
KR (1) KR20150039201A (https=)
CN (1) CN104884080A (https=)
AR (1) AR091977A1 (https=)
AU (1) AU2013296240B2 (https=)
BR (1) BR112015002321A2 (https=)
CA (1) CA2879763C (https=)
IL (1) IL236776A0 (https=)
MX (1) MX2015001508A (https=)
TW (1) TW201425332A (https=)
WO (1) WO2014022748A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811526T3 (es) 2010-12-30 2021-03-12 Lab Francais Du Fractionnement Glicoles como agentes de inactivación de patógenos
EP2879697A4 (en) 2012-08-03 2016-01-20 Lfb Usa Inc USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3016729B1 (fr) 2013-07-05 2020-03-25 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Matrice de chromatographie d'affinité
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
CA2281949A1 (en) 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US20060264357A1 (en) * 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
EP1776108A1 (en) 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20090148458A1 (en) 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
KR20140133958A (ko) 2005-10-21 2014-11-20 엘에프비 유에스에이, 인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및 사용 방법
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
EP2729164A4 (en) 2011-07-07 2015-05-06 Lfb Usa Inc FORMULATIONS STABILIZING PROTEINS
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
EP2879697A4 (en) 2012-08-03 2016-01-20 Lfb Usa Inc USE OF ANTITHROMBIN IN OXYGENATION OF EXTRACORPOREAL MEMBRANE

Also Published As

Publication number Publication date
IL236776A0 (en) 2015-03-31
US20140194360A1 (en) 2014-07-10
WO2014022748A1 (en) 2014-02-06
JP2015524823A (ja) 2015-08-27
CA2879763A1 (en) 2014-02-06
CN104884080A (zh) 2015-09-02
BR112015002321A2 (pt) 2019-10-22
CA2879763C (en) 2020-12-01
AU2013296240A1 (en) 2015-02-12
MX2015001508A (es) 2015-04-08
JP6389172B2 (ja) 2018-09-12
TW201425332A (zh) 2014-07-01
EP2879697A1 (en) 2015-06-10
AU2013296240B2 (en) 2018-05-17
US9511087B2 (en) 2016-12-06
AR091977A1 (es) 2015-03-11
EP2879697A4 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
KR20150039201A (ko) 체외 막 산소공급에서의 안티트롬빈의 용도
US20230000911A1 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
KR20140135219A (ko) 자간전증의 치료에서의 안티트롬빈의 용도
Rosa et al. An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
RU2596785C2 (ru) Композиция, содержащая пептид и ингибитор вирусной нейраминидазы
EA010650B1 (ru) Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
RU2290195C1 (ru) Средство с антикоагулянтной, антитромбоцитарной, антитромботической, фибриндеполимеризационной и фибринолитической активностями
KR20060126762A (ko) 외상의 말기 합병증을 치료하기 위한 인자 ⅴⅰⅰａ의 용도
US9546381B2 (en) Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
JP6294773B2 (ja) 口腔粘膜疾患の予防または治療用経口製剤
JP6289511B2 (ja) 羊水塞栓の治療剤
KR20120022717A (ko) 피브리노겐의 신규 용도
JP2009521513A (ja) 治療の方法
Cade et al. Effects of thrombolytic therapy on hemorrhage from post-operative wounds
Verstraete Report on a preparation of pectin: Sangostop®

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180802

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190719

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190719

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I